Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sars-CoV-2 Infection Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT07147517
View directory record Official record
Conditions
Respiratory Infection Virus, COVID -19, RSV, FLU
Interventions
Component A0, Component A1, Component A2, Component B
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
La Jolla, California • San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 27, 2026, 4:56 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

NCT04734860
View directory record Official record
Conditions
Covid19
Interventions
COVI-AMG, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Bradenton, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

Exercise in Adults with Post-Acute Sequelae of SARS-CoV-2 (COVID-19) Infection Study

NCT05218174
View directory record Official record
Conditions
COVID-19
Interventions
Exercise Prescription
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 27, 2026, 4:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pandemic-adapted Caries Care Multicentre Single-group Interventional Study

NCT04666597
View directory record Official record
Conditions
Dental Caries in Children
Interventions
Modified CariesCare International management
Procedure
Lead sponsor
Universidad El Bosque, Bogotá
Other
Eligibility
3 Years to 8 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 27, 2026, 4:56 AM EDT
Withdrawn Phase 3 Interventional

Outpatient Use of Ivermectin in COVID-19

NCT04530474
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin Pill, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT06511050
View directory record Official record
Conditions
Long Covid, Post-treatment Lyme Disease Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
Lumbrokinase
Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Not listed Phase 2 Interventional

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

NCT04840459
View directory record Official record
Conditions
Covid19
Interventions
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
Biological
Lead sponsor
Sohail Rao
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 1 Interventional

A Trial of NT-I7 in COVID-19 (SPESELPIS)

NCT04501796
View directory record Official record
Conditions
COVID-19
Interventions
Double-Blind NT-I7, Double-Blind Placebo
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
19 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting No phase listed Observational

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

NCT04362150
View directory record Official record
Conditions
COVID
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060
View directory record Official record
Conditions
COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
Interventions
APL-9, Vehicle Control
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 27, 2026, 4:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Tools for Wellbeing COVID-19 National Study of Undergraduate Students

NCT04414371
View directory record Official record
Conditions
Stress, Anxiety, Depression, Resilience, Wellbeing, Mood
Interventions
Yoga
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 27, 2026, 4:56 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
View directory record Official record
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding COVID-19 Testing Knowledge and Practices Among 2-1-1 Helpline Callers

NCT05812599
View directory record Official record
Conditions
Communication, Health Knowledge, Attitudes, Practice
Interventions
Educational Module
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 27, 2026, 4:56 AM EDT
Not listed Not applicable Interventional

Amygdala Insula Retraining in the Management of Long COVID Symptoms

NCT05851846
View directory record Official record
Conditions
Long COVID
Interventions
Amygdala insula retraining
Behavioral
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 27, 2026, 4:56 AM EDT
Not listed No phase listed Observational

Vocal Feature Analysis Algorithm for COVID-19 Detection

NCT04418544
View directory record Official record
Conditions
COVID-19
Interventions
Device used to record voice for screening
Device
Lead sponsor
Soniphi LLC
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

NCT04461353
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional

Mind Body Intervention for COVID-19 Long Haul Syndrome

NCT04854772
View directory record Official record
Conditions
COVID-19 Long Haul Syndrome
Interventions
Mind Body Syndrome Therapy for Long Covid
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Results available

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

NCT04523181
View directory record Official record
Conditions
Covid-19
Interventions
Antroquinonol, Placebo
Drug · Other
Lead sponsor
Golden Biotechnology Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Michigan City, Indiana • Wichita, Kansas • Rockville, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 2 Interventional Results available

Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

NCT04349371
View directory record Official record
Conditions
COVID, Coronavirus Infection
Interventions
Chloroquine, Placebo oral tablet
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

NCT04362137
View directory record Official record
Conditions
Cytokine Storm (Covid-19)
Interventions
Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

NCT04379518
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Recombinant Interferon Alfa-2b, Rintatolimod
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 27, 2026, 4:56 AM EDT